A water permeability-imparting agent containing an alkylene oxide adduct (A) of a polyvalent active hydrogen compound represented by Formula (1):

R—[O(A.sup.1O).sub.m—(CH.sub.2CH.sub.2O).sub.n—H].sub.1   (1)

wherein R represents a residue, after removal of all active hydrogen, of the polyvalent active hydrogen compound; A.sup.1O represents a C2 to C4 alkyleneoxy group; m represents an average addition mole number of A.sup.1O and is a number of 4 to 50; n represents an average addition mole number of CH.sub.2CH.sub.2O; and 1 represents a valence and is an integer of 3 to 6, and an average addition mole number ratio between A.sup.1O and CH.sub.2CH.sub.2O in Formula (1), n/m, is 0 to 0.5.

The invention relates to medicine, namely, to the solutions used for hemostasis. The hemostatic agent, which represents a polyammonia methanediamine chloride of the general formula

##STR00001##

where: n=1-20, m=1-10, at that n×m≧8.

The hemostatic agent may be applied in the form of a 0.01-10% aqueous solution. An aqueous solution of the preparation can be used for impregnation of materials used for bleeding arrest, suture material, bandaging material. The hemostatic agent may be used in the composition of a retraction cord, adhesive pastes, vaginal and rectal suppositories, creams, gels, as well as used with microchips that provide slow release of the preparation. The preparation can also be used in eye drops, eye ointments, and lubricants applied to the surface of the catheter. The drug can be used in endodontic treatment, may be injected into a polymer sealer for root canal obturation, as well as locally—by means of electrophoresis. The hemostatic agent may be used in conjunction with a gel based on aluminum sulphate or silver solution, and also with a polysaccharide haemostatic system. An efficient haemostatic preparation ensuring a significant analgetic effect is developed.

The invention relates to medicine, namely, to the solutions used for hemostasis. The hemostatic agent, which represents a polyammonia methanediamine chloride of the general formula

##STR00001##

where: n=1-20, m=1-10, at that n×m≧8.

The hemostatic agent may be applied in the form of a 0.01-10% aqueous solution. An aqueous solution of the preparation can be used for impregnation of materials used for bleeding arrest, suture material, bandaging material. The hemostatic agent may be used in the composition of a retraction cord, adhesive pastes, vaginal and rectal suppositories, creams, gels, as well as used with microchips that provide slow release of the preparation. The preparation can also be used in eye drops, eye ointments, and lubricants applied to the surface of the catheter. The drug can be used in endodontic treatment, may be injected into a polymer sealer for root canal obturation, as well as locally—by means of electrophoresis. The hemostatic agent may be used in conjunction with a gel based on aluminum sulphate or silver solution, and also with a polysaccharide haemostatic system. An efficient haemostatic preparation ensuring a significant analgetic effect is developed.

An absorbent article comprising a composition, said composition comprising a metathesized unsaturated polyol ester, said metathesized unsaturated polyol ester having one or more of the following properties: (i) a weight average molecular weight of from about 5,000 Daltons to about 50,000 Daltons; (ii) an oligomer index from greater than 0 to 1; (iii) an iodine value of from about 30 to about 200.

An absorbent article comprising a composition, said composition comprising a metathesized unsaturated polyol ester, said metathesized unsaturated polyol ester having one or more of the following properties: (i) a weight average molecular weight of from about 5,000 Daltons to about 50,000 Daltons; (ii) an oligomer index from greater than 0 to 1; (iii) an iodine value of from about 30 to about 200.

The present disclosure provides articles having an absorbent core with a plurality of segmented volumes defined by a network of filaments, with an absorbent material therein. Suitable articles which may be formed with this absorbent core include, for example, diapers such as infant diapers, juvenile diapers and training pants, feminine hygiene products such as menstrual pads, adult incontinence products such as adult briefs, protective underwear, pads and bladder control pads, pet training pads, and other disposable products utilized to absorb fluids.

The present disclosure provides articles having an absorbent core with a plurality of segmented volumes defined by a network of filaments, with an absorbent material therein. Suitable articles which may be formed with this absorbent core include, for example, diapers such as infant diapers, juvenile diapers and training pants, feminine hygiene products such as menstrual pads, adult incontinence products such as adult briefs, protective underwear, pads and bladder control pads, pet training pads, and other disposable products utilized to absorb fluids.

Composite materials made of a citrate, a calcium carbonate-containing material and an association moiety which is associated with the citrate and the calcium carbonate-containing material are provided. The composite materials are typically particulate materials (e.g., powdery materials). Compositions and articles-of-manufacturing containing and/or configured for applying the composite materials are also provided, as well as their use in inducing blood coagulation and arresting hemorrhage, including internal and/or massive hemorrhage.

An anti-microbial metal coating may be applied to filter membranes for use in actively depressing microbial viability in filtration applications. The anti-microbial metal coating may be applied to substrates that are considered to be sensitive to damage by conventional metal coating techniques or resistant to metal bonding. The coating may be applied from a salt absorbed to the substrate in solution, converted to a reducible form with a conversion agent, and reduced to active metal format through a low temperature plasma treatment.

An antibacterial medical biomaterial includes an acellular small intestinal submucosal matrix material, an antibacterial gel layer located on a surface of the acellular small intestinal submucosal matrix material, and an absorbable fiber layer located on a surface of the antibacterial gel layer. Sulfadiazine silver is on the surface of the acellular small intestinal submucosal matrix material and/or within the acellular small intestinal submucosal matrix material. An absorbable fiber layer to which the sulfadiazine silver is attached, wherein the content of sulfadiazine silver in the absorbable fiber is 1 wt. %˜2 wt. %. The medical biomaterial is usable as an external medicine for treating wound infections relayed by burns or wounds, and for reducing the incidence of infection by using a conventional central venous catheter with a sulfadiazine silver antibacterial coating, so that the medical biomaterial loaded with sulfadiazine silver also has antibacterial activity consistent with sulfadiazine silver.